Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03308929 · ClinicalTrials.gov registry record

Prospective G7 Dual Mobility Total Hip PMCF

A clinical trial of Survivorship and Safety, sponsored by Zimmer Biomet.

Active
Registry status
250
Enrollment target
6
Study locations

NCT03308929 is a study of Survivorship and Safety that is active but no longer recruiting, run by Zimmer Biomet. The registered enrollment target is 250 participants, above the 223-participant average among 36 other Survivorship trials with a reported enrollment target (12% higher). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03308929, a study of Survivorship and Safety, is active but no longer recruiting, sponsored by Zimmer Biomet.

ACTIVE NOT RECRUITING
Registry status
250 participants
Enrollment target
6
Study locations

Study Summary

This is a prospective multi-center clinical evaluation following recipients of the G7 Dual Mobility hip device. The primary objective is to characterize survivorship of the G7 hip at five years post-index procedure. Secondary objectives include documentation of clinical outcomes, safety and radiographic data.

Interventions

  • DEVICE G7 Dual Mobility hip

Study Locations (6)

Virginia

  • Tidewater Orthopaedics - Hampton
  • Ortho Virginia - Richmond

New Jersey

  • Jersey City Medical Center - Jersey City

New Mexico

  • New Mexico Orthopaedics - Albuquerque

North Carolina

  • University of North Carolina - Chapel Hill

Oregon

  • Oregon Health and Science University - Portland

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2017-02-28
Est. Completion 2029-02-28

Sponsor

Zimmer Biomet

115 total trials

What the Registry Record Tells You About NCT03308929

The ClinicalTrials.gov registry entry for NCT03308929 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 223-participant average among 36 other Survivorship trials with a reported enrollment target (12% higher). The listed sponsor is Zimmer Biomet, which has 115 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Survivorship appearing as the primary indexed condition, and to 1 intervention - of which G7 Dual Mobility hip is the first listed.

NCT03308929 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Virginia, New Jersey, New Mexico.

Frequently Asked Questions

What is clinical trial NCT03308929 about?

NCT03308929 is a clinical study titled "Prospective G7 Dual Mobility Total Hip PMCF". This is a prospective multi-center clinical evaluation following recipients of the G7 Dual Mobility hip device. The primary objective is to characterize survivorship of the G7 hip at five years post-index procedure. Secondary objectives include documentation of clinical outcomes, safety and radiogra...

What is the current status of trial NCT03308929?

This trial is currently active not recruiting. The enrollment target is 250 participants. The study started on 2017-02-28. Estimated completion is 2029-02-28.

What conditions does trial NCT03308929 study?

This clinical trial studies the following conditions: Survivorship, Safety, Clinical Outcomes, Functional Outcomes, Radiological Outcomes.

What interventions are being tested in trial NCT03308929?

The interventions under investigation include: G7 Dual Mobility hip (DEVICE).

Who is sponsoring clinical trial NCT03308929?

This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03308929 being conducted?

This trial has 6 study locations across New Jersey, New Mexico, North Carolina, Oregon, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Survivorship

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.